Paclitaxel (Taxol): An inhibitor of angiogenesis in a highly vascularized transgenic breast cancer

Derick H Lau, Ling Xue, Lawrence J. Young, Patricia A. Burke, Anthony T. Cheung

Research output: Contribution to journalArticlepeer-review

159 Scopus citations


Paclitaxel (Taxol), a promoter of microtubule polymerization and a radiosensitizing agent, is one of the more active anticancer drugs in the current treatment of solid tumors. In this study, we show that paclitaxel possesses an antiangiogenic property associated with a down-regulation of vascular endothelial growth factor (VEGF) in a highly-vascularized transgenic murine breast cancer (Met-1). Paclitaxel, at non-cytotoxic doses of 0, 3 and 6 mg/kg/day, was administered intraperitoneally for 5 days to nude mice bearing the Met-1 breast tumor. Extent of intratumoral angiogenesis, as indicated by microvessel tortuosity and microvessel density, was significantly reduced by paclitaxel in a dose-dependent manner. Paclitaxel also suppressed expression of VEGF in the Met-1 cells transplanted in nude mice or maintained in cell culture. These results indicate that antiangiogenesis associated with a down-regulation of VEGF is an additional mode of action of paclitaxel.

Original languageEnglish (US)
Pages (from-to)31-36
Number of pages6
JournalCancer Biotherapy and Radiopharmaceuticals
Issue number1
StatePublished - 1999


  • Anti-angiogenesis
  • Breast cancer
  • Paclitaxel
  • VEGF

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology


Dive into the research topics of 'Paclitaxel (Taxol): An inhibitor of angiogenesis in a highly vascularized transgenic breast cancer'. Together they form a unique fingerprint.

Cite this